uniQure 2025 Q3 Earnings Revenue Surges 61.8% as Net Loss Widens 81.5%

uniQure (QURE) reported fiscal 2025 Q3 results marked by a sharp revenue increase and a significantly widened net loss. The company’s total revenue rose to $3.70 million, surpassing 2024 Q3 by 61.8%, but fell short of FactSet estimates by $2.10 million. The net loss expanded to $80.53 million, or $1.38 per share, a 81.5% increase from the prior year. Despite the revenue growth, the stock price plummeted 49.90% month-to-date following FDA-related news, raising concerns about regulatory hurdles and financial sustainability.

Revenue

License revenue accounted for the majority of the total, contributing $3.58 million, while collaboration revenue added an additional $119,000. The 61.8% year-over-year increase reflects strong performance in licensing, though the company missed revenue projections by $2.10 million, underscoring challenges in monetizing its gene therapy pipeline.

Earnings/Net Income

The net loss widened to $80.53 million, or $1.38 per share, compared to $44.38 million, or $0.91 per share, in 2024 Q3. This represents a 51.6% increase in per-share losses and an 81.5% rise in absolute terms. The company has posted losses for 10 consecutive years in this quarter, highlighting persistent operational inefficiencies and heavy R&D costs. The EPS decline signals deteriorating profitability despite revenue gains.

Price Action

Post-earnings, uniQure’s stock surged 16.42% in a single trading day and rose 1.31% weekly, but the month-to-date decline of 49.90% reflects investor skepticism. The sharp drop on November 3, 2025, following FDA feedback on AMT-130’s BLA submission, exacerbated volatility. The stock’s erratic performance underscores market uncertainty about regulatory approval timelines and financial viability.

Post-Earnings Price Action Review

The stock’s post-earnings trajectory revealed a mixed response from investors. A 16.42% single-day rally indicated short-term optimism, but the broader month-to-date plunge of nearly 50% highlighted deepening concerns over the FDA’s rejection of AMT-130’s data sufficiency. This regulatory setback, coupled with the company’s widening losses, eroded investor confidence. The 1.31% weekly gain suggests some resilience, yet the persistent downward trend reflects skepticism about uniQure’s ability to navigate regulatory and financial challenges.

Additional News

Recent developments include multiple law firms investigating uniQure for potential securities fraud. The DJS Law Group and Kessler Topaz Meltzer & Check, LLP are probing claims of misleading statements regarding AMT-130’s BLA prospects, while the Schall Law Firm is pursuing similar allegations. These investigations follow a 60%+ stock price drop on November 3, 2025, triggered by FDA feedback. Investors are urged to contact these firms to discuss potential claims.